# 617892

AMYOTROPHIC LATERAL SCLEROSIS, SUSCEPTIBILITY TO, 24; ALS24


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
4q33 {Amyotrophic lateral sclerosis, susceptibility to, 24} 617892 AD 3 NEK1 604588
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal dominant
RESPIRATORY
- Respiratory insufficiency (in some patients)
ABDOMEN
Gastrointestinal
- Dysphagia
NEUROLOGIC
Central Nervous System
- Dysphagia
- Dysarthria
- Amyotrophic paresis, asymmetric (upper limbs initially)
- Upper and lower motor neuron signs
- Bulbar symptoms develop with time
- Tetraparesis
- Hyperreflexia without spasticity in atrophic limbs
- Atrophy of the hippocampus, severe, seen on MRI
- Atrophy of the caudate and thalamus
- Impaired nonverbal memory
MISCELLANEOUS
- Onset between ages 54 to 75
MOLECULAR BASIS
- Susceptibility conferred by mutation in the never in mitosis gene A-related kinase 1 gene (NEK1, 604588.0005)
Amyotrophic lateral sclerosis - PS105400 - 35 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p36.22 Frontotemporal lobar degeneration, TARDBP-related AD 3 612069 TARDBP 605078
1p36.22 Amyotrophic lateral sclerosis 10, with or without FTD AD 3 612069 TARDBP 605078
2p13.1 {Amyotrophic lateral sclerosis, susceptibility to} AR, AD 3 105400 DCTN1 601143
2q33.1 Amyotrophic lateral sclerosis 2, juvenile AR 3 205100 ALS2 606352
2q34 Amyotrophic lateral sclerosis 19 AD 3 615515 ERBB4 600543
2q35 Amyotrophic lateral sclerosis 22 with or without frontotemporal dementia AD 3 616208 TUBA4A 191110
3p11.2 Amyotrophic lateral sclerosis 17 AD 3 614696 CHMP2B 609512
4q33 {Amyotrophic lateral sclerosis, susceptibility to, 24} AD 3 617892 NEK1 604588
5q31.2 Amyotrophic lateral sclerosis 21 AD 3 606070 MATR3 164015
5q35.3 Frontotemporal dementia and/or amyotrophic lateral sclerosis 3 AD 3 616437 SQSTM1 601530
6q21 Amyotrophic lateral sclerosis 11 AD 3 612577 FIG4 609390
9p21.2 Frontotemporal dementia and/or amyotrophic lateral sclerosis 1 AD 3 105550 C9orf72 614260
9p13.3 ?Amyotrophic lateral sclerosis 16, juvenile AR 3 614373 SIGMAR1 601978
9p13.3 Amyotrophic lateral sclerosis 14, with or without frontotemporal dementia 3 613954 VCP 601023
9q34.13 Amyotrophic lateral sclerosis 4, juvenile AD 3 602433 SETX 608465
10p13 Amyotrophic lateral sclerosis 12 3 613435 OPTN 602432
10q22.3 Amytrophic lateral sclerosis 23 AD 3 617839 ANXA11 602572
12q13.12 {Amyotrophic lateral sclerosis, susceptibility to} AR, AD 3 105400 PRPH 170710
12q13.13 Amyotrophic lateral sclerosis 20 AD 3 615426 HNRNPA1 164017
12q13.3 {Amyotrophic lateral sclerosis, susceptibility to, 25} AD 3 617921 KIF5A 602821
12q14.2 Frontotemporal dementia and/or amyotrophic lateral sclerosis 4 AD 3 616439 TBK1 604834
12q24.12 {Amyotrophic lateral sclerosis, susceptibility to, 13} AD 3 183090 ATXN2 601517
12q24.12 Spinocerebellar ataxia 2 AD 3 183090 ATXN2 601517
14q11.2 Amyotrophic lateral sclerosis 9 3 611895 ANG 105850
15q21.1 Amyotrophic lateral sclerosis 5, juvenile AR 3 602099 SPG11 610844
16p11.2 Amyotrophic lateral sclerosis 6, with or without frontotemporal dementia 3 608030 FUS 137070
17p13.2 Amyotrophic lateral sclerosis 18 3 614808 PFN1 176610
18q21 Amyotrophic lateral sclerosis 3 AD 2 606640 ALS3 606640
20p13 Amyotrophic lateral sclerosis 7 2 608031 ALS7 608031
20q13.32 Amyotrophic lateral sclerosis 8 AD 3 608627 VAPB 605704
21q22.11 Amyotrophic lateral sclerosis 1 AR, AD 3 105400 SOD1 147450
22q11.23 Frontotemporal dementia and/or amyotrophic lateral sclerosis 2 AD 3 615911 CHCHD10 615903
22q12.2 ?{Amyotrophic lateral sclerosis, susceptibility to} AR, AD 3 105400 NEFH 162230
Xp11.21 Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia XLD 3 300857 UBQLN2 300264
Not Mapped Amyotrophic lateral sclerosis, juvenile, with dementia 205200 ALSDC 205200

TEXT

A number sign (#) is used with this entry because of evidence that susceptibility to amyotrophic lateral sclerosis-24 (ALS24) is conferred by heterozygous mutation in the NEK1 gene (604588) on chromosome 4q33.

For a phenotypic description and a discussion of genetic heterogeneity of amyotrophic lateral sclerosis, see ALS1 (105400).


Clinical Features

Brenner et al. (2016) reported 3 patients with amyotrophic lateral sclerosis with truncating mutations in the NEK1 gene. The first patient presented at age 54 with upper and lower motor neuron signs in the left arm. Symptoms spread to the leg and right side, and within 2 years bulbar signs had developed. The patient was alive at the time of the report. The second patient presented at age 59 with dysphagia, and within 2 years had developed dysarthria, myatrophic paresis of the left arm, and respiratory insufficiency, while the lower extremities were not affected. Hyperreflexia was present in the atrophic limb. The patient died at the age of 63. The patient's mother had died of ALS at the age of 62 after a 5-year disease progression with onset in the hands and progression to tetraparesis. Late in the disease she developed bulbar symptoms and had a gastrostoma. The third patient presented at the age of 75 years with asymmetric amyotrophic paresis of the first dorsal interosseous muscle of the left hand. Within 18 months the disease had progressed to an asymmetric amyotrophic tetraparesis with asymmetric hyperreflexia without spasticity in all limbs, early pseudobulbar dysarthria, dysphagia, and mild respiratory insufficiency. She was still alive 18 months after disease onset. This patient had an affected uncle who died of ALS at the age of 70; detailed medical history was not available. Cognitive impairment was either not clinically evident or absent upon testing in all patients, but the third patient showed atypical hippocampal/temporal frontal lobe functions, such as nonverbal memory, as well as severe hippocampal atrophy and atrophy of caudate and thalamus seen on MRI.


Molecular Genetics

To identify potential loss-of-function variants in the NEK1 gene in familial ALS, Brenner et al. (2016) analyzed whole-exome sequence data from 265 familial ALS patients and 827 control individuals. They identified 3 patients with NEK1 truncating mutations: a 1-bp deletion (c.42_42delA, Ser14SerfsTer45) and 2 nonsense mutations (S1036X, 604588.0005 and R812X, 604588.0006). One potential loss-of-function mutation was found in the control group (allele frequency = 0.06%), in agreement with the high frequency of similar NEK1 mutations in the ExAC database (allele frequency = 0.05%). Additionally, the S1036X mutation was found in a brother of a proband, who was without symptoms of ALS 4 years after the death of the proband and 9 years after onset of symptoms in the proband. These findings suggested a reduced penetrance of heterozygous NEK1 loss-of-function mutations.

Kenna et al. (2016) conducted whole-exome analyses of 1,022 index familial ALS cases and 7,315 controls. They also performed gene-burden analyses trained with established ALS genes and identified a significant association between loss-of-function variants in NEK1 and familial ALS risk. Independently, autozygosity mapping for an isolated community in the Netherlands identified a NEK1 arg261-to-his (R261H; 604588.0007) variant as a candidate risk factor. Replication analyses of sporadic ALS cases and independent control cohorts confirmed significant disease association for both the R261H (10,589 samples analyzed) and NEK1 loss-of-function variants (3,362 samples analyzed). In total, NEK1 risk variants were observed in nearly 3% of ALS cases.


REFERENCES

  1. Brenner, D., Muller, K., Wieland, T., Weydt, P., Bohm, S., Lule, D., Hubers, A., Neuwirth, C., Weber, M., Borck, G., Wahlqvist, M., Danzer, K. M., Volk, A. E., Meitinger, T., Strom, T. M., Otto, M., Kassubek, J., Ludolph, A. C., Andersen, P. M., Weishaupt J. H. NEK1 mutations in familial amyotrophic lateral sclerosis. Brain 139: e28, 2016. Note: Electronic Article. [PubMed: 26945885, related citations] [Full Text]

  2. Kenna, K. P., van Doormaal, P. T., Dekker, A. M., Ticozzi, N., Kenna, B. J., Diekstra, F. P., van Rheenen, W., van Eijk, K. R., Jones, A. R., Keagle, P., Shatunov, A., Sproviero, W., and 70 others. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature Genet. 48: 1037-1042, 2016. [PubMed: 27455347, related citations] [Full Text]


Creation Date:
Ada Hamosh : 02/28/2018
carol : 02/01/2019
alopez : 02/28/2018

# 617892

AMYOTROPHIC LATERAL SCLEROSIS, SUSCEPTIBILITY TO, 24; ALS24


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
4q33 {Amyotrophic lateral sclerosis, susceptibility to, 24} 617892 Autosomal dominant 3 NEK1 604588

TEXT

A number sign (#) is used with this entry because of evidence that susceptibility to amyotrophic lateral sclerosis-24 (ALS24) is conferred by heterozygous mutation in the NEK1 gene (604588) on chromosome 4q33.

For a phenotypic description and a discussion of genetic heterogeneity of amyotrophic lateral sclerosis, see ALS1 (105400).


Clinical Features

Brenner et al. (2016) reported 3 patients with amyotrophic lateral sclerosis with truncating mutations in the NEK1 gene. The first patient presented at age 54 with upper and lower motor neuron signs in the left arm. Symptoms spread to the leg and right side, and within 2 years bulbar signs had developed. The patient was alive at the time of the report. The second patient presented at age 59 with dysphagia, and within 2 years had developed dysarthria, myatrophic paresis of the left arm, and respiratory insufficiency, while the lower extremities were not affected. Hyperreflexia was present in the atrophic limb. The patient died at the age of 63. The patient's mother had died of ALS at the age of 62 after a 5-year disease progression with onset in the hands and progression to tetraparesis. Late in the disease she developed bulbar symptoms and had a gastrostoma. The third patient presented at the age of 75 years with asymmetric amyotrophic paresis of the first dorsal interosseous muscle of the left hand. Within 18 months the disease had progressed to an asymmetric amyotrophic tetraparesis with asymmetric hyperreflexia without spasticity in all limbs, early pseudobulbar dysarthria, dysphagia, and mild respiratory insufficiency. She was still alive 18 months after disease onset. This patient had an affected uncle who died of ALS at the age of 70; detailed medical history was not available. Cognitive impairment was either not clinically evident or absent upon testing in all patients, but the third patient showed atypical hippocampal/temporal frontal lobe functions, such as nonverbal memory, as well as severe hippocampal atrophy and atrophy of caudate and thalamus seen on MRI.


Molecular Genetics

To identify potential loss-of-function variants in the NEK1 gene in familial ALS, Brenner et al. (2016) analyzed whole-exome sequence data from 265 familial ALS patients and 827 control individuals. They identified 3 patients with NEK1 truncating mutations: a 1-bp deletion (c.42_42delA, Ser14SerfsTer45) and 2 nonsense mutations (S1036X, 604588.0005 and R812X, 604588.0006). One potential loss-of-function mutation was found in the control group (allele frequency = 0.06%), in agreement with the high frequency of similar NEK1 mutations in the ExAC database (allele frequency = 0.05%). Additionally, the S1036X mutation was found in a brother of a proband, who was without symptoms of ALS 4 years after the death of the proband and 9 years after onset of symptoms in the proband. These findings suggested a reduced penetrance of heterozygous NEK1 loss-of-function mutations.

Kenna et al. (2016) conducted whole-exome analyses of 1,022 index familial ALS cases and 7,315 controls. They also performed gene-burden analyses trained with established ALS genes and identified a significant association between loss-of-function variants in NEK1 and familial ALS risk. Independently, autozygosity mapping for an isolated community in the Netherlands identified a NEK1 arg261-to-his (R261H; 604588.0007) variant as a candidate risk factor. Replication analyses of sporadic ALS cases and independent control cohorts confirmed significant disease association for both the R261H (10,589 samples analyzed) and NEK1 loss-of-function variants (3,362 samples analyzed). In total, NEK1 risk variants were observed in nearly 3% of ALS cases.


REFERENCES

  1. Brenner, D., Muller, K., Wieland, T., Weydt, P., Bohm, S., Lule, D., Hubers, A., Neuwirth, C., Weber, M., Borck, G., Wahlqvist, M., Danzer, K. M., Volk, A. E., Meitinger, T., Strom, T. M., Otto, M., Kassubek, J., Ludolph, A. C., Andersen, P. M., Weishaupt J. H. NEK1 mutations in familial amyotrophic lateral sclerosis. Brain 139: e28, 2016. Note: Electronic Article. [PubMed: 26945885] [Full Text: https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/aww033]

  2. Kenna, K. P., van Doormaal, P. T., Dekker, A. M., Ticozzi, N., Kenna, B. J., Diekstra, F. P., van Rheenen, W., van Eijk, K. R., Jones, A. R., Keagle, P., Shatunov, A., Sproviero, W., and 70 others. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature Genet. 48: 1037-1042, 2016. [PubMed: 27455347] [Full Text: https://dx.doi.org/10.1038/ng.3626]


Creation Date:
Ada Hamosh : 02/28/2018
Edit History:
carol : 02/01/2019
alopez : 02/28/2018